Balyasny Asset Management’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $493K | Sell |
2,197
-45
| -2% | -$11.2K | ﹤0.01% | 2371 |
|
|
2025
Q4 | $540K | Buy |
+2,242
| New | +$573K | ﹤0.01% | 2490 |
|
|
2025
Q3 | – | Sell |
-3,077
| Closed | -$840K | – | 3391 |
|
|
2025
Q2 | $794K | Sell |
3,077
-172
| -5% | -$41K | ﹤0.01% | 2127 |
|
|
2025
Q1 | $727K | Buy |
3,249
+1,768
| +119% | +$413K | ﹤0.01% | 2131 |
|
|
2024
Q4 | $339K | Buy |
+1,481
| New | +$357K | ﹤0.01% | 2339 |
|
|
2024
Q3 | – | Sell |
-3,791
| Closed | -$847K | – | 3101 |
|
|
2024
Q2 | $726K | Buy |
+3,791
| New | +$769K | ﹤0.01% | 1914 |
|
|
2024
Q1 | – | Sell |
-3,090
| Closed | -$566K | – | 3045 |
|
|
2023
Q4 | $532K | Sell |
3,090
-383
| -11% | -$58.8K | ﹤0.01% | 1929 |
|
|
2023
Q3 | $514K | Sell |
3,473
-7,337
| -68% | -$1.33M | ﹤0.01% | 1749 |
|
|
2023
Q2 | $2.36M | Buy |
10,810
+3,421
| +46% | +$762K | 0.01% | 1329 |
|
|
2023
Q1 | $1.62M | Sell |
7,389
-29,050
| -80% | -$6.3M | ﹤0.01% | 1535 |
|
|
2022
Q4 | $7.58M | Buy |
+36,439
| New | +$8.01M | 0.02% | 848 |
|
|
2022
Q3 | – | Sell |
-98,763
| Closed | -$20.7M | – | 3206 |
|
|
2022
Q2 | $20.7M | Buy |
+98,763
| New | +$21M | 0.07% | 413 |
|
|
2022
Q1 | – | Sell |
-252,754
| Closed | -$65.8M | – | 2787 |
|
|
2021
Q4 | $65.8M | Buy |
252,754
+198,805
| +369% | +$51.6M | 0.23% | 86 |
|
|
2021
Q3 | $14.2M | Buy |
+53,949
| New | +$14.8M | 0.06% | 443 |
|
|
2020
Q2 | – | Sell |
-3,292
| Closed | -$485K | – | 1435 |
|
|
2020
Q1 | $485K | Buy |
+3,292
| New | +$524K | 0.01% | 915 |
|
|
2018
Q4 | – | Sell |
-18,575
| Closed | -$2.14M | – | 1699 |
|
|
2018
Q3 | $2.14M | Sell |
18,575
-9,364
| -34% | -$1.03M | 0.01% | 951 |
|
|
2018
Q2 | $2.89M | Buy |
27,939
+17,900
| +178% | +$1.81M | 0.01% | 818 |
|
|
2018
Q1 | $989K | Sell |
10,039
-7,508
| -43% | -$709K | ﹤0.01% | 1205 |
|
|
2017
Q4 | $1.49M | Sell |
17,547
-2,074
| -11% | -$171K | ﹤0.01% | 1233 |
|
|
2017
Q3 | $1.51M | Sell |
19,621
-232,766
| -92% | -$17.8M | 0.01% | 1038 |
|
|
2017
Q2 | $19.7M | Sell |
252,387
-43,411
| -15% | -$3.11M | 0.08% | 317 |
|
|
2017
Q1 | $21.3M | Buy |
295,798
+47,829
| +19% | +$3.31M | 0.1% | 272 |
|
|
2016
Q4 | $15.4M | Buy |
+247,969
| New | +$15.2M | 0.08% | 348 |
|
|
2015
Q3 | – | Sell |
-278,257
| Closed | -$15.7M | – | 1346 |
|
|
2015
Q2 | $15.7M | Buy |
+278,257
| New | +$17.6M | 0.1% | 272 |
|
Other funds holding RMD
VCM
VPM
DAM
Balyasny Asset Management's RMD Position: Q1 2026 in Review
Balyasny Asset Management reduced its ResMed (RMD) stake by 2% in Q1 2026, selling an estimated $11.2K and leaving 2,197 shares worth $493K. The position accounts for ﹤0.01% of the portfolio, ranked #2371.
Balyasny Asset Management first reported a position in RMD in Q2 2015 and has held it in 24 quarters since. The position peaked at $65.8M in Q4 2021. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.
- Balyasny Asset Management held 2,197 shares of ResMed worth $493K as of Q1 2026.
- Balyasny Asset Management sold 45 ResMed shares in Q1 2026, an estimated $11.2K.
- ResMed made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2371 holding.
- Balyasny Asset Management first reported a position in ResMed in Q2 2015 and has held it in 24 quarters since.
- Balyasny Asset Management's ResMed position peaked at $65.8M in Q4 2021.
- 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.